TAXUS PHARMACEUTICALS HOLDINGS, INC.: 10-Q/A filed 2017-04-11
What TAXUS PHARMACEUTICALS HOLDINGS, INC. reported in its quarterly report amendment filed 2017-04-11 (fiscal Q2 2017): 19 published measures, 51 facts as tagged in accession 0001549727-17-000020.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-Q/A (quarterly report amendment)
- Filed
- 2017-04-11
- Fiscal period
- fiscal Q2 2017
- Accession
- 0001549727-17-000020 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TAXUS PHARMACEUTICALS HOLDINGS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 30,107 | USD | |
| At 2016-06-30 | 63,955 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | -63,408 | USD | |
| At 2016-06-30 | -11,961 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 6,344 | USD | |
| At 2016-06-30 | 29,310 | USD | |
| At 2015-12-31 | 28,622 | USD | |
| At 2015-06-30 | 13,773 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -12,301 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -51,447 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -34,686 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -97,546 | USD | 184 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-12-31 | -22,966 | USD | 184 |
| 2015-07-01 to 2015-12-31 | -125,151 | USD | 184 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 363 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 5,851 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 13,913 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 32,188 | USD | 184 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-12-31 | 140,000 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | -637,825 | USD | |
| At 2016-06-30 | -586,378 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 27,107 | USD | |
| At 2016-06-30 | 53,467 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 93,515 | USD | |
| At 2016-06-30 | 75,916 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 20,763 | USD | |
| At 2016-06-30 | 24,157 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 91 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 1,462 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 4,731 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 10,214 | USD | 184 |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 272 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 4,389 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 9,182 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 21,974 | USD | 184 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 12,392 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 52,909 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 39,417 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 107,760 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 81,500,200 | shares | |
| At 2016-06-30 | 81,500,200 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 573,602 | USD | |
| At 2016-06-30 | 573,602 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 2,500 | USD | |
| At 2016-06-30 | 2,500 | USD |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -5,166 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -21,608 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -14,568 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -40,969 | USD | 184 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-12-31 | 3,394 | USD | 184 |
| 2015-07-01 to 2015-12-31 | 5,012 | USD | 184 |
Inspect the source
- Entity
- TAXUS PHARMACEUTICALS HOLDINGS, INC. / CIK 0001622676
- Captured
- SEC response SHA-256
e3218558022f67a41c23ca87687a0fc1e62f07559dbc817c1e43f7cd112051e5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001622676.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))